 The main purpose of this study is to compare the safety, effectiveness and tolerability of using Pegasys with Copegus in people who have both the hepatitis C virus HCV genotype 1 and HIV who continue taking HAART highly active antiretroviral therapy to those who discontinue taking HAART. 